Related Experiment Video

Updated: Apr 19, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Ongoing challenges for pharmacotherapy for dyslipidemia

Anthony D Pisaniello1, Daniel J Scherer, Yu Kataoka

  • 1University of Adelaide, South Australian Health and Medical Research Institute , PO Box 11060, Adelaide, SA, 5001 , Australia +61 8 8128 4510 ; stephen.nicholls@sahmri.com.

Expert Opinion on Pharmacotherapy
|December 6, 2014
PubMed
Abstract

Insights

Maximizing statin use in high-risk patients is crucial for cardiovascular disease prevention. Novel lipid-modifying therapies, such as PCSK9 and CETP inhibitors, show promise for additional protection but require further clinical validation.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Lipid Metabolism

Background:

  • Lipid-modifying therapies are vital for cardiovascular disease (CVD) prevention guidelines.
  • Current use of these agents is suboptimal, leaving a significant residual risk of clinical events.
  • There is a pressing need for more effective lipid-modifying strategies for many patients.

Purpose of the Study:

  • To review factors affecting the utilization of current lipid-modifying treatments.
  • To explore emerging therapeutic agents targeting various lipid factors.
  • To identify gaps and opportunities in lipid management for CVD prevention.

Main Methods:

  • A comprehensive literature search was conducted.
  • Focus was placed on manuscripts discussing established lipid-modifying therapies.
  • New agents in development targeting diverse lipid factors were also examined.

Main Results:

  • Statin therapy is underutilized in high-risk populations.
  • Novel therapeutic targets, including proprotein convertase subtilisin kexin-type 9 (PCSK9) and cholesteryl ester transfer protein (CETP), are under investigation.
  • Further research is needed to confirm the efficacy of these new agents.

Conclusions:

  • Intensified efforts are necessary to optimize statin utilization in patients at higher risk.
  • Emerging therapies like PCSK9 and CETP inhibitors may offer enhanced cardiovascular protection.
  • Clinical trials are essential to validate the benefits of these novel lipid-modifying approaches.
Keywords:
atherosclerosiscardiovascular risklipid-modifying therapylipids

More Related Videos

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs08:18

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

1.7K
Assessing Whole-Body Lipid-Handling Capacity in Mice07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

5.0K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.9K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
642
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
105
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
365
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
425
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
321